N4 Pharma announces positive in vivo results from first Nuvec® study for Inflammatory Bowel Disease (IBD) dual-loaded with siRNA and mRNA
May.29, 2025 in
News
N4 Pharma has successfully completed its first in vivo study of Nuvec® delivered orally using its lead programme N4 101, an orally administered anti-inflammatory treatment for IBD. In the study, both single (siRNA) and dual-loaded (siRNA and mRNA) Nuvec® formulations were tested to explore whether the combination enhances overall therapeutic effect, and both demonstrated marked improvements of t
Comments Off on N4 Pharma announces positive in vivo results from first Nuvec® study for Inflammatory Bowel Disease (IBD) dual-loaded with siRNA and mRNA
